4-[(4-氯苯基)硫基]哌啶盐酸盐 | 101798-64-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4-[(4-氯苯基)硫基]哌啶盐酸盐
• 英文名称: 4-[(4-chlorophenyl)thio]piperidine· hydrochloride
• 英文别名: 4-[(4-Chlorophenyl)thio]piperidine monohydrochloride；4-((4-Chlorophenyl)thio)piperidine hydrochloride；4-(4-chlorophenyl)sulfanylpiperidine;hydrochloride
• CAS: 101798-64-5
• 化学式: C₁₁H₁₄ClNS*ClH
• 分子量: 264.219
• InChiKey: UPCRGRQCVDATBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.61
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  37.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  1-甲基-4-巯基哌啶 在 盐酸 、 氢氧化钾 、 溶剂黄146 、 sodium nitrite 作用下， 以 甲苯 为溶剂， 反应 5.5h， 生成 4-[(4-氯苯基)硫基]哌啶盐酸盐
  参考文献：
  名称：

  安吡托林脱氮杂衍生物的合成及镇痛活性

  摘要：

  Anpirtoline 的新 deaza 衍生物已通过三种不同的方法合成。已经研究了它们的受体结合谱（5-HT1A、5-HT1B）和镇痛活性（热板、乙酸诱导的扭体）。

  DOI：

  10.1002/(sici)1521-4184(19991)332:1<13::aid-ardp13>3.0.co;2-l

文献信息

• N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and
  申请人：A. H. Robins Company, Inc.

  公开号：US04593102A1

  公开（公告）日：1986-06-03

  Novel pyrrolidine, piperidine and homopiperidinecarboxamide and thiocarboxamide compounds having the formula: ##STR1## wherein X is --S--, --S(O)-- or --S(O).sub.2 --; A is a loweralkalene chain and A.sup.1 and A.sup.2 are alkalene chains when p and d are one; R, R.sup.1 and R.sup.2 are hydrogen, loweralkyl, phenyl cycloalkyl or phenylalkyl and R.sup.1 and R.sup.2 may form a heterocyclic residue with the adjacent nitrogen atom; Q is a selected aromatic radical, and the pharmaceutically acceptable acid addition salts useful as cardiac antiarrhythmia agents are disclosed. Novel chemical intermediates, unsubstituted on pyrrolidine, piperidine and homopiperidine nitrogen but with --(A.sup.2).sub.p --X--(A.sup.2).sub.d --Q side chain are also disclosed.

  新型吡咯烷、哌啶和高哌啶羧酰胺及硫代羧酰胺化合物，具有如下通式：##STR1## 其中X为--S--、--S(O)--或--S(O)2--；A为低级烷撑链，当p和d为1时，A1和A2为烷撑链；R、R1和R2为氢、低级烷基、苯基、环烷基或苯基烷基，且R1和R2可与相邻的氮原子形成杂环残基；Q为选定的芳香基团，以及作为心脏抗心律失常药物使用的药用可接受酸加成盐被公开。还公开了在吡咯烷、哌啶和高哌啶氮原子上未取代，但具有--(A2)p--X--(A2)d--Q侧链的新型化学中间体。
• N-(amino)alkyl)-1-pyrrolidine, 1-piperidine and
  申请人：A. H. Robins Company, Incorporated

  公开号：US04642348A1

  公开（公告）日：1987-02-10

  Novel pyrrolidine, piperidine and homopiperidinecarboxamide and thiocarboxamide compounds having the formula: ##STR1## wherein X is --S--, --S(O)-- or --S(O).sub.2 --; A is a loweralkalene chain and A.sup.1 and A.sup.2 are alkalene chains when p and d are one; R, R.sup.1 and R.sup.2 are hydrogen, loweralkyl, phenyl cycloalkyl or phenylalkyl and R.sup.1 and R.sup.2 may form a heterocyclic residue with the adjacent nitrogen atom; Q is a selected aromatic radical, and the pharmaceutically acceptable acid addition salts useful as cardiac antiarrhythmia agents are disclosed. Novel chemical intermediates, unsubstituted on pyrrolidine, piperidine and homopiperidine nitrogen but with --(A.sup.2).sub.p --X--(A.sup.2).sub.d --Q side chain are also disclosed.

  新型吡咯烷、哌啶和高哌啶羧酰胺及硫代羧酰胺化合物，具有如下通式：##STR1## 其中X为--S--、--S(O)--或--S(O)2--；A为低级烷撑链，当p和d为一时，A1和A2为烷撑链；R、R1和R2为氢、低级烷基、苯基、环烷基或苯基烷基，且R1和R2可与相邻的氮原子形成杂环残基；Q为选定的芳香基团，并公开了作为心脏抗心律失常剂的药用可接受的酸加成盐。还公开了在吡咯烷、哌啶和高哌啶氮上未取代但带有--(A2)p--X--(A2)d--Q侧链的新型化学中间体。
• N-[(Amino)Alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulphur linked substitution in the 2, 3 or 4-position
  申请人：A.H. ROBINS COMPANY, INCORPORATED

  公开号：EP0160436A2

  公开（公告）日：1985-11-06

  Pyrrolidine, piperidine and homopiperidine- carboxamide and thiocarboxamide compounds of the formula: wherein X is -S-, -S(0)- or -S(0)2-; A is a loweralkalene chain and A1 and A2 are alkalene chains when p and d are one; R, R1 and R2 are hydrogen, loweralkyl, phenyl cycloalkyl or phenylalkyl and R1 and R2 may form a heterocyclic residue with the adjacent nitrogen atom; Q is a selected aromatic radical, and the pharmaceutically acceptable acid addition salts are useful as cardiac antiarrhythmia agents. Chemical intermediates, unsubstituted on pyrrolidine, piperidine and homopiperidine nitrogen but with the -(A2)p-X-(A2)d-Q side chain are also disclosed.

  式中的吡咯烷、哌啶和均哌啶-羧酰胺和硫代羧酰胺化合物： 其中，X 是-S-、-S(0)- 或-S(0)2-；A 是低级烯烃链，当 p 和 d 为 1 时，A1 和 A2 是烯烃链；R、R1 和 R2 是氢、低级烷基、苯基环烷基或苯基烷基，R1 和 R2 可与相邻的氮原子形成杂环残基；Q 是选定的芳香基，药学上可接受的酸加成盐可用作抗心律失常剂。 还公开了吡咯烷、哌啶和高哌啶氮上未取代但具有-(A2)p-X-(A2)d-Q 侧链的化学中间体。
• AMINE DERIVATIVES
  申请人：Tadeka Chemical Industries, Ltd.

  公开号：EP1227090A1

  公开（公告）日：2002-07-31

  A compound of the formula:    wherein X and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents; R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents; Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms; ... represents a single bond or a double bond; T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; and Ar represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.

  式中的化合物 X和X'相同或不同，各自代表氢原子、氟原子、氯原子或可选具有取代基的氨基，且X和X'中至少有一个代表氟原子、氯原子或可选具有取代基的氨基； R1 和 R2 代表氢原子或任选具有取代基的 C1-6 烷基，或 R1 和 R2 与相邻的氮原子一起形成任选具有取代基的含氮杂环； Y 和 Q 相同或不同，各自代表主链为 1 至 6 个原子的键或间隔物； 代表单键或双键； T1 和 T2 相同或不同，当相邻......中的每一个为单键时，各自代表 C(R9)（R9 代表氢原子、羟基或 C1-6 烷基）或 N，当相邻......中的每一个为双键时，各自代表 C；以及 Ar 代表任选具有取代基的芳香基、任选具有取代基的 C3-9 环烷基、任选具有取代基的 3-9 元饱和杂环基、氢原子或卤素原子；条件是 6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-(4-苯基哌嗪-1-基)羰基氨基]丙酰基]-1,2,3,4-四氢喹啉；6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-4-(2-氧代-2,3-二氢-1H-苯并咪唑-1-基)哌啶甲酰氨基]丙酰基]-1,2,3,4-四氢喹啉不包括 1-苯甲酰基-N-[(R)-2-[6-氯-3-[(N,N-二甲基氨基)甲基]-1,2,3,4-四氢喹啉-1-基]-1-[3-(吲哚-3-基)丙酰基]-4-哌啶甲酰胺；其盐或其原药具有优异的抑制体生长抑素受体结合的作用，可用于预防和/或治疗与体生长抑素相关的疾病。
• US4593102A
  申请人：——

  公开号：US4593102A

  公开（公告）日：1986-06-03